Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

The follicle‑stimulating hormone and luteinising hormone components bind to specific receptors on ovarian cells, triggering signaling pathways that promote follicular growth, estrogen production, and the final ovulatory surge. This coordinated action enables the development of mature oocytes and prepares the reproductive tract for possible conception.

The dose of Meriofert is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s clinical condition, response to treatment, and monitoring results. Dosing regimens are not standardized and must follow the prescribing information.

Meriofert is not intended for use during an established pregnancy and should only be used under strict medical supervision when pregnancy is desired. Limited safety data are available for breastfeeding; clinicians should weigh potential risks and benefits before prescribing to nursing mothers.

To order Meriofert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Meriofert combines both FSH and LH activity in a single injectable, whereas some alternatives provide only FSH (e.g., recombinant FSH) or require separate LH supplementation. This dual action can simplify protocols for certain patients, but the choice depends on individual response, treatment goals, and physician preference.

Meriofert must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period, it may be used, but it should be returned to the refrigerator promptly.

Meriofert is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique, typically in a clinical setting, following the dosing schedule prescribed by the treating physician.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause rapid weight gain, abdominal pain, and respiratory compromise, as well as the possibility of multiple pregnancy and rare allergic reactions such as anaphylaxis. Patients should be closely monitored for these complications.

Meriofert is contraindicated in individuals with known hypersensitivity to any component of the formulation, in patients with active ovarian cysts, uncontrolled thyroid disease, or severe uncontrolled endocrine disorders. It should also be avoided in women who are already pregnant unless specifically indicated by a specialist.